Thomas VanCott, Ph.D., is the CEO at Excellos, leveraging extensive experience in strategic leadership within the biotech sector. With a strong foundation in chemistry from Dickinson College and a Ph.D. in physical chemistry from the University of Virginia, they have held senior roles at various organizations, including Chief Technology & Strategy Officer at Catalent Cell & Gene Therapy and President & CEO of ABL Inc. Their career highlights include directing preclinical vaccine R&D at the Henry M. Jackson Foundation and leading innovation in vaccine development during their tenure with the US Army. Recognized for their ability to integrate scientific expertise with corporate management, Thomas effectively guides organizations in navigating complex bioservices and biotech challenges.
Location
San Diego, United States
This person is not in the org chart
This person is not in any teams
This person is not in any offices